Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Local surgery or radiotherapy for oligoprogressive lesions during encorafenib + binimetinib in BRAF V600-mutant melanoma
2024-516073-74-00Phase 4Completed
- Sponsor
- SRH Wald-Klinikum Gera GmbH
- Start
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of encorafenib and binimetinib in melanoma (3 cohorts), sponsored by SRH Wald-Klinikum Gera GmbH. Primary endpoint: Progression-free survival after local treatment. Started Jan 2025; status: completed.
02
Drugs
encorafenibbinimetinib
03
Conditions
melanoma
Beyond the preview
Go deeper on 2024-516073-74-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516073-74-00.